Literature DB >> 4015225

Oophorectomy and colon cancer. Impact on survival.

G H Ballantyne, M M Reigel, B G Wolff, D M Ilstrup.   

Abstract

Data on survival and survival free-from-recurrence were analyzed retrospectively in a group of 571 women who had undergone curative resection for colon cancer at the Mayo Clinic between 1972 and 1978. Of these women, 75 (group 1) had required bilateral oophorectomy before or at colon resection, while 496 (group 2) retained one or both ovaries. Average age, location and grade of tumor, and duration of follow-up were similar for both groups. Five-year-survival rate for the 571 women was 73.6%, as compared with 84.3% for matched controls. The 5-year survival rates were not significantly different for group 1 (78.0%) and group 2 (72.9%). Five-year survival free-from-recurrence also was not significantly different (82.9%, group 1 and 79.5%, group 2). Women in group 1 who had grade 1 or 2 tumors or lesions in the sigmoid and cecum fared the best (no significant difference from controls). Incidence studies of ovarian metastases from colon cancers suggest that three to eight per cent of women should benefit from bilateral oophorectomy. This agrees with the difference in survival observed between groups 1 and 2 in this study. Our sample size is too small to statistically confirm the reliability of this difference. The design of a prospective study testing this hypothesis is outlined.

Entities:  

Mesh:

Year:  1985        PMID: 4015225      PMCID: PMC1250875          DOI: 10.1097/00000658-198508000-00011

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  16 in total

1.  Surgical procedures for carcinoma of the left colon and rectum, with five-year end results following abdominopelvic dissection of lymph nodes.

Authors:  M R DEDDISH
Journal:  Am J Surg       Date:  1960-02       Impact factor: 2.565

2.  The prognostic significance of direct extension of carcinoma of the colon and rectum.

Authors:  V B ASTLER; F A COLLER
Journal:  Ann Surg       Date:  1954-06       Impact factor: 12.969

3.  Prophylactic oophorectomy with resection of the large bowel for cancer.

Authors:  C V BURT
Journal:  Am J Surg       Date:  1951-11       Impact factor: 2.565

4.  Prophylactic oophorectomy in conjunction with large-bowl resection for cancer: report of two cases.

Authors:  K Antoniades; H B Spector; R H Hecksher
Journal:  Dis Colon Rectum       Date:  1977-09       Impact factor: 4.585

5.  The challenge of metastatic ovarian carcinoma.

Authors:  S L Israel; E V Helsel; D H Hausman
Journal:  Am J Obstet Gynecol       Date:  1965-12-15       Impact factor: 8.661

6.  Resected ovarian recurrence from colorectal adenocarcinoma: a study of 13 cases.

Authors:  S L Blamey; F T McDermott; E Pihl; E S Hughes
Journal:  Dis Colon Rectum       Date:  1981 May-Jun       Impact factor: 4.585

7.  Prophylactic oophorectomy and colorectal cancer in premenopausal patients.

Authors:  J M MacKeigan; J A Ferguson
Journal:  Dis Colon Rectum       Date:  1979-09       Impact factor: 4.585

8.  Ovarian involvement in adenocarcinoma of the colon and rectum.

Authors:  S Blamey; F McDermott; E Pihl; A B Price; B J Milne; E Hughes
Journal:  Surg Gynecol Obstet       Date:  1981-07

9.  Metachronous ovarian metastases from adenocarcinoma of the colon and rectum.

Authors:  L O Herrera; E J Ledesma; N Natarajan; G E Lopez; Y Tsukada; A Mittelman
Journal:  Surg Gynecol Obstet       Date:  1982-04

10.  Prophylactic oophorectomy in colorectal carcinoma.

Authors:  H O Graffner; P O Alm; J E Oscarson
Journal:  Am J Surg       Date:  1983-08       Impact factor: 2.565

View more
  2 in total

1.  Bilateral ovarian micrometastatic adenocarcinoma upon prophylactic oophorectomy concurrent with low anterior resection for rectal cancer.

Authors:  Robin Irons; Erin McIntosh; Alexandre Hageboutros; David Warshal; Steven McClane
Journal:  World J Surg Oncol       Date:  2017-02-07       Impact factor: 2.754

2.  Ovarian metastases from primary gastrointestinal malignancies: the Royal Marsden Hospital experience and implications for adjuvant treatment.

Authors:  A E Taylor; V M Nicolson; D Cunningham
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.